---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-003431"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T12:24:24.901190+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech announces Nasdaq uplisting and pricing of $15M public offering at $4.25/unit

## Summary
- Common stock begins trading on Nasdaq Capital Market under PMCB on August 10, 2021.
- Public offering of 3,529,412 units at $4.25 per unit (1 share + 1 warrant); gross proceeds ~$15M.
- Warrants exercisable at $4.25, immediately, expire in 5 years; pre-funded warrants also offered.
- H.C. Wainwright sole book-runner; underwriter granted 30-day option for up to 529,411 additional units.
- Executive officers and directors subject to 90-day lock-up from prospectus supplement date.

## SEC filing metadata
- accession: 0001683168-21-003431
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316821003431/0001683168-21-003431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316821003431/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-003431
- JSON: https://secwatch.observer/filing/0001683168-21-003431.json
- Plain text: https://secwatch.observer/filing/0001683168-21-003431.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.